Search

Simulations Plus Inc

Cerrado

SectorSanidad

18.23 -0.38

Resumen

Variación precio

24h

Actual

Mínimo

18.17

Máximo

18.3

Métricas clave

By Trading Economics

Ingresos

-960K

3.6M

Ventas

-2.4M

22M

P/B

Media del Sector

45.825

64.641

BPA

0.3

Margen de beneficios

16.335

Empleados

212

EBITDA

-6.3M

1.1M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

-5.38% downside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-453K

371M

Apertura anterior

18.61

Cierre anterior

18.23

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

138 / 340 Clasificación en Healthcare

Simulations Plus Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

1 ago 2026, 19:01 UTC

News
Correlated Moves

Ethereum is trading lower, reflecting a broader decline in correlated assets. It remains below its 20-day moving average amid routine market fluctuations.

1 ago 2026, 00:06 UTC

Social Media
News

TLT trades lower in after-market hours, reflecting a historically bearish period for bonds and targeting the $80 level amid rising interest rate expectations.

1 ago 2026, 00:06 UTC

News

Geopolitical tensions with Iran have boosted the United States Oil Fund LP, following President Trump's ordered military offensive in response to attacks on U.S. troops.

1 ago 2026, 00:06 UTC

News

Ameriprise Financial Inc shares are lower in after-market trading, despite strong second-quarter revenue of $4.90 billion and adjusted EPS of $11.07.

1 ago 2026, 00:02 UTC

News

UBS raised its price target on Hershey Co to $198, maintaining a Neutral rating. Shares are trading higher during after-market hours.

1 ago 2026, 00:02 UTC

News

Lattice Semiconductor shares are lower in after-market trading following a cautionary report citing declining sales and rising costs, with shares priced at $124.53.

1 ago 2026, 00:02 UTC

News

Snap Inc. shares rose to about $4.70 in after-market hours, supported by bullish options activity ahead of its August 3 earnings report.

1 ago 2026, 00:02 UTC

News
Social Media

NVIDIA Corp shares are lower in after-market hours amid broader market declines, despite recent strong performance relative to peers and a weekly gain.

1 ago 2026, 00:02 UTC

News

Lockheed Martin secured a $107.29 million Navy contract for VH-92A rotor blade design, boosting shares in after-market hours.

1 ago 2026, 00:02 UTC

News
Correlated Moves

JPMorgan Chase & Co shares are lower in after-market trading amid ongoing market rotation and rising bond yields affecting investor sentiment.

1 ago 2026, 00:02 UTC

News

KKR & Co Inc reported record Q2 revenue of $6.31 billion. Shares declined in after-market trading despite strong earnings and net income growth.

1 ago 2026, 00:02 UTC

News

Exponent Inc shares are trading lower in after-market hours after UBS lowered its price target to $72 while maintaining a Neutral rating.

1 ago 2026, 00:02 UTC

News

Bloom Energy Corp is declining in after-market hours amid a class action lawsuit alleging securities fraud and broader market pressures.

1 ago 2026, 00:01 UTC

News

Quantum Corp shares are higher in after-market trading, supported by positive developments in the quantum computing industry and strong investor interest in the sector.

1 ago 2026, 00:01 UTC

News

UBS raised its price target on Bright Horizons to $88, as shares gain in after-market trading following three sessions of declines.

1 ago 2026, 00:01 UTC

News

Regeneron Pharmaceuticals shares are lower in after-market hours following a class action lawsuit alleging securities fraud and concerns over a failed clinical trial.

1 ago 2026, 00:01 UTC

News

Newell Brands Inc shares are lower in after-market hours amid overall market declines. The company entered a five-year credit facility of up to $800 million.

1 ago 2026, 00:01 UTC

News

UBS raised its price target on Valero Energy Corp to $355, contributing to shares' gain during after-market hours on Friday.

1 ago 2026, 00:01 UTC

News

UBS maintains Buy rating on Saia Inc, lowering price target to $504. Shares are higher in after-market trading following the adjustment.

1 ago 2026, 00:01 UTC

News

Alnylam Pharmaceuticals shares are lower in after-market hours, reflecting broader market declines despite a strong second-quarter revenue of $1.2 billion.

1 ago 2026, 00:01 UTC

News

American Electric Power reported Q2 earnings of $1.36 per share and raised its 2026 guidance to $6.25 to $6.55, driving shares higher in after-market hours.

1 ago 2026, 00:01 UTC

News

Clean Energy Fuels Corp is trading lower in after-market hours following a cautionary analysis highlighting its subpar revenue growth and high production costs.

1 ago 2026, 00:01 UTC

News

Chevron Corp has reached an accord with Iraq to invest in two oil fields, enhancing production capabilities. Shares are trading higher in after-market hours.

31 jul 2026, 23:56 UTC

News

Citigroup maintained its Buy rating on Welltower and raised its price target to $275. Shares are modestly higher in after-market trading.

31 jul 2026, 23:56 UTC

News

Citigroup maintained its Buy rating on Neurocrine Biosciences and raised its price target to $249. Shares are higher in after-market trading.

31 jul 2026, 23:51 UTC

Social Media
Correlated Moves
News

Meta Platforms Inc shares are lower in after-market hours, pressured by broader market weakness and concerns over rising AI spending following a disappointing earnings report.

31 jul 2026, 23:46 UTC

News

3M shares declined in after-market trading amid concerns over insider selling by EVP Kevin H. Rhodes, who sold $1.3 million worth of stock.

31 jul 2026, 23:41 UTC

Social Media
News
Correlated Moves

Goldman Sachs shares declined in after-market trading amid broader market turmoil and hedge fund degrossing linked to losses on leveraged AI investments.

31 jul 2026, 23:41 UTC

News

JPMorgan Chase & Co. shares are lower in after-market trading following a note highlighting ongoing market rotation and challenges from rising long-term Treasury yields.

31 jul 2026, 23:36 UTC

News

Carvana shares declined in after-market trading following Citigroup's price target cut to $90, amid broader market weakness from Apple's disappointing guidance.

Comparación entre iguales

Cambio de precio

Simulations Plus Inc previsión

Precio Objetivo

By TipRanks

-5.38% descenso

Estimación a 12 Meses

Media 17.25 USD  -5.38%

Máximo 18.5 USD

Mínimo 16 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Simulations Plus Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

4 ratings

0

Comprar

4

Mantener

0

Vender

Sentimiento

By Acuity

138 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat